News
Biotech group Neuren Pharmaceuticals has reported a 14% uptick in quarterly US sales of its Retts syndrome treatment Daybue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback